Bosutinib versus placebo for autosomal dominant polycystic kidney disease

Keyphrases

• Placebo 100%
• Autosomal Dominant Polycystic Kidney Disease (ADPKD) 100%
• Bosutinib 100%
• Kidney Enlargement 20%
• Adverse Events 10%
• Magnetic Resonance Imaging Scan 10%
• Liver 10%
• Overactivation 10%
• Treatment Duration 10%
• Toxicity Profile 10%
• Gastrointestinal Toxicity 10%
• Intent-to-treat 10%
• Gastrointestinal 10%
• BCR-ABL Inhibitors 10%
• Liver Toxicity 10%
• EGFR Decline 10%
• Protocol Amendments 10%
• Kidney Growth 10%
• Total Kidney Volume 10%

Medicine and Dentistry

• Polycystic Kidney Disease 100%
• Placebo 100%
• Bosutinib 100%
• Epidermal Growth Factor Receptor 20%
• Kidney Hypertrophy 20%
• Adverse Event 10%
• Intention-to-Treat Analysis 10%
• Magnetic Resonance Imaging 10%
• Gastrointestinal Toxicity 10%
• Liver Toxicity 10%
• Kidney Development 10%
• Bcr-Abl Tyrosine-Kinase Inhibitor 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Placebo 100%
• Kidney Polycystic Disease 100%
• Bosutinib 100%
• Epidermal Growth Factor Receptor 20%
• Kidney Hypertrophy 20%
• Adverse Event 10%
• Protein Tyrosine Kinase Inhibitor 10%
• Gastrointestinal Toxicity 10%
• Hepatotoxicity 10%
• Abelson Kinase 10%